What is the current Price Target for the Seelos Therapeutics, Inc. stock?

The average Seelos Therapeutics, Inc. target price is $512.00. This is 165,008.00% higher than the current stock price. 1 Analyst has issued a Seelos Therapeutics, Inc. price target 2025.

How high will the Seelos Therapeutics, Inc. stock rise?

No reliable answer can be given as to how high the Seelos Therapeutics, Inc. stock will rise. The performance of stocks, including the Seelos Therapeutics, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Seelos Therapeutics, Inc. stock today?

The performance of Seelos Therapeutics, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Seelos Therapeutics, Inc. stock fall?

The decline in Seelos Therapeutics, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Seelos Therapeutics, Inc. Forecast, price target & analysts

$0.31

3.33% yesterday

Nasdaq, Nov 25, 03:30 pm CET

ISIN

US81577F1093

Symbol

SEEL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Seelos Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

Seelos Therapeutics, Inc. Classifications & Recommendation:

Buy

100%

Seelos Therapeutics, Inc. Price Target

Target Price	$512.00
Price	$0.31
Potential	165,008.00% register free of charge
Number of Estimates	1

	1 Analyst has issued a Seelos Therapeutics, Inc. price target 2025. The average Seelos Therapeutics, Inc. target price is $512.00. This is 165,008.00% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Seelos Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Seelos Therapeutics, Inc. stock has an average upside potential 2025 of 165,008.00% register free of charge . Most analysts recommend the Seelos Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-989.53	-4.09
	4,671.12%	99.59%
P/E		negative

1 Analysts have issued a Seelos Therapeutics, Inc. forecast for earnings per share. The average Seelos Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-989.53	4,671.12%
2024	$-4.09 99.59% Unlock

Current	0.00	100.00%

Seelos Therapeutics, Inc....

Discover more stocks with a high price target

Valneva 284.61%

CureVac N.V. 145.33%

Moderna 70.75%

Bavarian Nordic 61.25%

Nel ASA 44.74%

Aixtron 43.84%

Volkswagen VZ 41.85%

Alibaba Group Holding Ltd 40.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now